India’s Dr Reddy’s has sold the US and Canadian rights to its 25mg/ml Elyxyb (celecoxib) oral solution to US-based BioDelivery Sciences International, for an upfront payment of $6m, followed by $9m within one year from closing the deal.
Dr. Reddy's Laboratories Ltd. has announced the sale of the US and Canadian rights to its value-added 25mg/ml Elyxyb (celecoxib) oral solution to BioDelivery Sciences International, a US based biotechnology company.
Dr Reddy’s said that it was entering into a definitive asset purchase agreement, under which the Indian company will receive...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
